Related Experiment Videos
Disseminated intravascular coagulation in solid tumors: clinical and pathologic study.
S Sallah1, J Y Wan, N P Nguyen
1Department of Medicine, University of Tennessee Health Science Center, Memphis 38103, USA. ssallah@utmem.edu
Thrombosis and Haemostasis
|October 5, 2001
Summary
Disseminated intravascular coagulation (DIC) affects 6.8% of solid tumor patients, with older age, male gender, and advanced cancer as risk factors. Developing DIC significantly worsens patient survival, highlighting the need for better management strategies.
Area of Science:
- Oncology
- Hematology
- Pathophysiology
Background:
- Disseminated intravascular coagulation (DIC) is a recognized complication in patients with solid tumors.
- Understanding the incidence and risk factors for DIC in this population is crucial for patient management.
Purpose of the Study:
- To evaluate the occurrence, clinical and laboratory features, and survival impact of DIC in patients with solid tumors.
Main Methods:
- Retrospective analysis of 1117 patients with solid tumors.
- Diagnosis of DIC based on established criteria.
- Multivariate analysis to identify independent risk factors for DIC.
- Comparison of survival rates between patients with and without DIC.
Main Results:
- DIC was diagnosed in 76 (6.8%) patients.
- Common coagulation abnormalities included thrombocytopenia, hypofibrinogenemia, elevated D-dimer, and fibrinogen degradation products.
- Independent risk factors for DIC were older age, male gender, advanced malignancies, breast cancer, and tumor necrosis.
- Patients with DIC had significantly inferior survival compared to those without DIC.
Conclusions:
- Specific clinical and laboratory factors are associated with DIC occurrence in solid tumor patients.
- DIC occurrence independently impacts survival in cancer patients.
- Further research is needed to optimize prophylactic strategies for DIC in at-risk patients.